An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol

Trials. 2024 Jul 5;25(1):457. doi: 10.1186/s13063-024-08302-7.

Abstract

This article reports an update to the protocol of the IMASOY trial, which was prospectively registered on clinicaltrials.gov (NCT04110340) in October 2019.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Aminoglycosides / administration & dosage
  • Aminoglycosides / adverse effects
  • Aminoglycosides / therapeutic use
  • Animals
  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / adverse effects
  • Anti-Bacterial Agents* / therapeutic use
  • Ciprofloxacin* / administration & dosage
  • Ciprofloxacin* / adverse effects
  • Ciprofloxacin* / therapeutic use
  • Drug Therapy, Combination
  • Equivalence Trials as Topic
  • Humans
  • Plague / drug therapy
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Ciprofloxacin
  • Anti-Bacterial Agents
  • Aminoglycosides

Associated data

  • ClinicalTrials.gov/NCT04110340